Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 228 participants.

Also called NCT07119372

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 228 participants (planned count) (from the registry)
Sponsor
  • Biocad Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07119372
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07119372. Randomized; no masking; primary purpose treatment. Start 2025-03-01 (actual); primary completion 2026-05-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Condition
Anemia
Condition
Chronic Kidney Disease Patients on Hemodialysis
Condition
Chronic Kidney Disease 5D
Intervention (Biological)
BCD-131 (pegdarbepoetin beta)
Intervention (Biological)
Mircera (methoxypolyethylene glycol-epoetin beta)
Lead sponsor
Biocad (class: industry)

Record details

Record id
cardio:ct-nct07119372
Content hash
a8f3ba90fe3d1ea2daf54a9fb8dd5f158af6037a64546e6274d7e93ad6b410e8